Trending

sales

Zolgensma hits the ground running, says Novartis

Zolgensma hits the ground running, says Novartis

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that

X

Zolgensma hits the ground running, says Novartis

https://pharmaphorum.com/news/zolgensma-hits-the-ground-running-says-novartis/

Supporting the pharmaceutical salesforce with digital marketing

Supporting the pharmaceutical salesforce with digital marketing

As marketers, we often wonder how we can best get our concept and product information to our customers,

X

Supporting the pharmaceutical salesforce with digital marketing

https://pharmaphorum.com/views-and-analysis/supporting-the-pharmaceutical-salesforce-with-digital-marketing/

Sales executive

Sales executive

This is an exciting opportunity to join a high growth digital media company, which has both online publications

X

Sales executive

https://pharmaphorum.com/jobs/sales-executive-publishing-division/

Roche beats revenue forecasts as sales of old drugs take off in China

Roche beats revenue forecasts as sales of old drugs take off in China

Roche has beaten analysts’ revenue forecasts in the third quarter, after mounting sales of its older drugs in

X

Roche beats revenue forecasts as sales of old drugs take off in China

https://pharmaphorum.com/news/roche-beats-revenue-forecasts-as-sales-of-old-drugs-take-off-in-china/

GSK’s Luke Miels demands new focus, and cost cuts

GSK’s Luke Miels demands new focus, and cost cuts

Further details have emerged about GlaxoSmithKline’s attempts to reinvigorate its business under new CEO Emma Walmsley. According to

X

GSK’s Luke Miels demands new focus, and cost cuts

https://pharmaphorum.com/news/gsks-new-management-demands-cost-cuts-rd-focus/

Zytiga is powerhouse for J&J – but for how long?

Zytiga is powerhouse for J&J – but for how long?

J&J to ‘vigorously defend’ blockbuster’s patent

X

Zytiga is powerhouse for J&J – but for how long?

https://pharmaphorum.com/news/zytiga-powerhouse-jj-long/

Drama as Roche’s Tecentriq fails in key bladder cancer trial

Drama as Roche’s Tecentriq fails in key bladder cancer trial

Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could

X

Drama as Roche’s Tecentriq fails in key bladder cancer trial

https://pharmaphorum.com/news/drama-roche-tecentriq-fails-key-bladder-cancer-trial/

Novo enjoys strong Q1 as Trump price crackdown fails to materialise

Novo enjoys strong Q1 as Trump price crackdown fails to materialise

Novo Nordisk has shaken off fears of a drug pricing crackdown from president Donald Trump, after it beat profit

X

Novo enjoys strong Q1 as Trump price crackdown fails to materialise

https://pharmaphorum.com/news/novo-nordisk-strong-q1/

Novo completes major filings for blockbuster hope semaglutide

Novo completes major filings for blockbuster hope semaglutide

Novo Nordisk has its weekly diabetes hopeful semaglutide filed in five key markets, after submitting a dossier in

X

Novo completes major filings for blockbuster hope semaglutide

https://pharmaphorum.com/news/novos-semaglutide-filed-five-key-markets/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com